10 First Approvals To Look Out For In 2018
Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.
You may also be interested in...
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.
The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.